Z-N-甲基-D-丙氨酸 | 68223-03-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: Z-N-甲基-D-丙氨酸
• 中文别名: N-苄氧羰基-N-甲基-D-丙氨酸；氯吡苯脲
• 英文名称: (R)-2-(((benzyloxy)carbonyl)(methyl)amino)propanoic acid
• 英文别名: N-[(benzyloxy)carbonyl]-N-methyl-D-alanine；Z-D-Meala-OH；(2R)-2-[methyl(phenylmethoxycarbonyl)amino]propanoic acid
• CAS: 68223-03-0
• 化学式: C₁₂H₁₅NO₄
• 分子量: 237.255
• InChiKey: QGEQKVZQPWSOTI-SECBINFHSA-N

物化性质

• 熔点：
  215-219℃
• 沸点：
  389.5±31.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Z-D-Meala-oh
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Z-D-Meala-oh
CAS number: 68223-03-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H15NO4
Molecular weight: 237.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Z-N-甲基-D-丙氨酸 在 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以41%的产率得到Benzyl ((S)-1-(((1S,2R)-4-((tert-butyldiphenylsilyl)oxy)-1-(furan-2-yl)-2-methylbutyl)(methyl)amino)-1-oxopropan-2-yl)(methyl)carbamate [2.18.1g]
  参考文献：
  名称：

  CYCLIC PEPTIDES AND USE AS MEDICINES

  摘要：

  本发明提供了一种化合物I的公式；或其药学上可接受的盐，其中变量R1、R2、R3、R4、R5和A-B在此处定义，这些化合物是非免疫抑制剂、环肽酶结合剂、mPTP阻滞剂，因此可用于预防或治疗HCV感染、中风、多发性硬化、HBV感染、HPV感染、哮喘、癌症、肌萎缩症、败血症、缺血/再灌注损伤和心力衰竭等疾病或紊乱。

  公开号：

  US20140134132A1
• 作为产物：
  描述：

  N-benzyloxycarbonyl-D-alanine 、 碘甲烷 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.25h， 以91%的产率得到Z-N-甲基-D-丙氨酸
  参考文献：
  名称：

  模拟 TNF 超家族成员 CD40L 同源三聚体的小型多价结构：描绘结构和效应器功能之间的关系

  摘要：

  合成的多价配体，由于存在与中央支架相连的识别基序的多个拷贝，可以介导细胞表面受体的聚集，从而起到效应分子的作用。本文剖析了靶向 CD40 的合成多价配体的结构和效应子功能之间的关系，CD40 是肿瘤坏死因子受体 (TNF-R) 超家族的细胞表面受体。在体内触发 CD40 信号可用于增强对细胞内病原体或肿瘤的免疫力。通过系统地改变中央支架的形状和价态、接头的性质和长度以及受体结合基序的序列，已经制备了一系列多聚体分子。此处报告的数据 (i) 表明 CD40 结合单位的径向分布和 C3 对称性是与 CD40 和信号传导的最佳结合的首选，(ii) 强调选择合适的接头将受体结合基序连接到中心的重要性支架，以及 (iii) 展示了平面环状 α 和 β 肽作为 CD40L 模拟物设计模板的多功能性。特别是，(Ahx)3-B 三聚体支架-接头组合同样容纳了来自不同 CD40L 热点区域的结合元件，包括 AA"

  DOI：

  10.1021/ja073169m

文献信息

• Macrocyclic Modulators of the Ghrelin Receptor
  申请人：Ocera Therapeutics, Inc.

  公开号：US20180110824A1

  公开（公告）日：2018-04-26

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了一种新颖的构象定义明确的大环化合物，已经证明是生长激素分泌素受体（GHS-R1a及其亚型、异构体和变体）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂，用于治疗和预防一系列医疗状况，包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、遗传疾病、过度增殖性疾病和炎症性疾病。
• Small Multivalent Architectures Mimicking Homotrimers of the TNF Superfamily Member CD40L:  Delineating the Relationship between Structure and Effector Function
  作者：Nathalie Trouche、Sébastien Wieckowski、Weimin Sun、Olivier Chaloin、Johan Hoebeke、Sylvie Fournel、Gilles Guichard

  DOI：10.1021/ja073169m

  日期：2007.11.1

  Synthetic multivalent ligands, owing to the presence of multiple copies of a recognition motif attached to a central scaffold, can mediate clustering of cell surface receptors and thereby function as effector molecules. This paper dissects the relationship between structure and effector function of synthetic multivalent ligands targeting CD40, a cell surface receptor of the tumor necrosis factor receptor

  合成的多价配体，由于存在与中央支架相连的识别基序的多个拷贝，可以介导细胞表面受体的聚集，从而起到效应分子的作用。本文剖析了靶向 CD40 的合成多价配体的结构和效应子功能之间的关系，CD40 是肿瘤坏死因子受体 (TNF-R) 超家族的细胞表面受体。在体内触发 CD40 信号可用于增强对细胞内病原体或肿瘤的免疫力。通过系统地改变中央支架的形状和价态、接头的性质和长度以及受体结合基序的序列，已经制备了一系列多聚体分子。此处报告的数据 (i) 表明 CD40 结合单位的径向分布和 C3 对称性是与 CD40 和信号传导的最佳结合的首选，(ii) 强调选择合适的接头将受体结合基序连接到中心的重要性支架，以及 (iii) 展示了平面环状 α 和 β 肽作为 CD40L 模拟物设计模板的多功能性。特别是，(Ahx)3-B 三聚体支架-接头组合同样容纳了来自不同 CD40L 热点区域的结合元件，包括 AA"
• [EN] CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR CGRP
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2018178938A1

  公开（公告）日：2018-10-04

  The disclosures herein relate to novel compounds of formula (IA) wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function. The disclosures herein also relates to novel compounds of formula(IB) wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function. The disclosures herein also relate to novel compounds of formula (IC) wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

  本公开涉及式(I A)的新化合物，其中R1、R2、R3和R4如本文所定义，并其在治疗、预防、改善、控制或减少与CGRP受体功能相关的脑血管或血管疾病中的用途。本公开还涉及到式(IB)的新化合物，其中R1、R2和R3如本文所定义，并其在治疗、预防、改善、控制或减少与CGRP受体功能相关的脑血管或血管疾病中的用途。本公开还涉及到式(IC)的新化合物，其中Ar1和R1如本文所定义，并其在治疗、预防、改善、控制或减少与CGRP受体功能相关的脑血管或血管疾病中的用途。
• A Building Block Approach for the Total Synthesis of YM‐385781
  作者：Yu Zhu、Siyue Liu、Johnny Zigmond、Kevin M. Kaltenbronn、Kendall J. Blumer、Kevin D. Moeller

  DOI：10.1002/ejoc.202300365

  日期：2023.5.22

  A building block approach to the synthesis of YM- and FR-analogs has been developed and utilized for the synthesis of YM-385781. The structure of the final analog was confirmed both spectroscopically and through biological assays, and it was interesting to note that even the less potent synthetic analog made here was able to inhibit both oncogenic Gq signaling and uveal melanoma cell growth.

  已开发出合成 YM 和 FR 类似物的构建模块方法，并将其用于 YM-385781 的合成。最终类似物的结构通过光谱和生物测定得到证实，有趣的是，即使是这里制造的效力较低的合成类似物也能够抑制致癌的 Gq 信号传导和葡萄膜黑色素瘤细胞的生长。
• CGRP receptor antagonists
  申请人：Heptares Therapeutics Limited

  公开号：US10259812B2

  公开（公告）日：2019-04-16

  The disclosures herein relate to novel compounds of formula wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

  本文所披露的内容涉及新型式化合物 其中 R1、R2 和 R3 如本文所定义，以及它们在治疗、预防、改善、控制或减少与 CGRP 受体功能相关的脑血管或血管疾病中的用途。